Juan A. Arnaiz

Quick facts

Marketed products

• Antiretroviral therapy alone
• Antiretroviral therapy plus Interleukin-2 · Immunology / Infectious Disease
  This combination uses antiretroviral drugs to suppress HIV replication while interleukin-2 enhances immune cell proliferation and function to restore CD4+ T-cell counts.
• Atazanavir / Ritonavir + Tenofovir / Emtricitabine · Infectious Disease / Virology
  This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
• Continue Ritonavir-boosted PI+Rosuvastatin · Infectious Disease / Cardiovascular
  This combination uses ritonavir-boosted protease inhibitor antiretroviral therapy to suppress HIV replication, while rosuvastatin reduces cholesterol levels to manage cardiovascular risk in HIV-positive patients.
• Darunavir/r · Infectious Disease
  Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.
• Darunavir / Ritonavir + Tenofovir / Emtricitabine · Infectious Disease / Virology
  This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps.
• elvitegravir/cobicistat/emtricitabine/tenofovir · Infectious Disease / Virology
  This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication by inhibiting integrase, blocking protease activity, and inhibiting reverse transcriptase.
• Fosfomycin and imipenem · Infectious Disease
  Fosfomycin and imipenem together provide dual antibiotic action by inhibiting bacterial cell wall synthesis through different mechanisms to treat serious infections.
• HAART + Immunotherapy · Immunology, Infectious Disease, Oncology
  HAART (highly active antiretroviral therapy) suppresses HIV replication while immunotherapy enhances the immune system's ability to recognize and eliminate HIV-infected cells and tumors.
• Switch ritonavir-boosted PI · Infectious Disease
  A ritonavir-boosted protease inhibitor combination that inhibits HIV protease to prevent viral replication and reduce viral load.
• tenofovir + emtricitabine + atazanavir-ritonavir · Infectious Disease / Virology
  This combination inhibits HIV reverse transcriptase and protease to block viral replication at multiple steps.
• Tenofovir + emtricitabine + lopinavir/ritonavir · Infectious Disease / Virology
  This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.

Phase 3 pipeline

• ATV/r plus ABC/3TC · Infectious Disease / Virology
  This combination uses atazanavir/ritonavir (protease inhibitors) plus abacavir/lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes.
• ATV/r + TDF/FTC or DRV/r + TDF/FTC · Infectious Disease / Virology
  This is a combination antiretroviral regimen that uses protease inhibitors (boosted with ritonavir) plus nucleoside reverse transcriptase inhibitors to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes.
• EFV plus ABC/3TC or RPV/TDF/FTC · Infectious Disease / Virology
  This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication.
• EFV/TDF/FTC · Infectious Disease / Virology
  This is a fixed-dose combination of three antiretroviral agents that work together to inhibit HIV replication through different mechanisms: efavirenz blocks reverse transcriptase, while tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors.
• Other ART regimens · Infectious Disease / Virology
  Other ART regimens refer to alternative antiretroviral therapy combinations used to treat HIV infection when standard first-line regimens are not suitable or have failed.
• RAL plus ABC/3TC · Infectious Disease / Virology
  This combination uses raltegravir (an integrase inhibitor) plus abacavir and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication through multiple mechanisms.
• Raltegravir/3TC · Infectious Disease
  Raltegravir/3TC is an integrase strand transfer inhibitor (INSTI) and a nucleoside reverse transcriptase inhibitor (NRTI) combination used to treat HIV-1 infection.

Phase 1 pipeline

• MVA-B

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Juan A. Arnaiz portfolio CI brief
• Juan A. Arnaiz pipeline updates RSS